* In talks over sale of unit
* Says may keep profitable ATG-Fresenius S drug
* Shares indicated up 0.2 pct
(Adds more details, outlook)
FRANKFURT, Dec 14 German healthcare group
Fresenius will exit its loss-making biotech business
in order to focus on its other businesses, which it said offer
better growth opportunities.
Fresenius said on Friday it was in talks with several
parties over a sale of Fresenius Biotech, which had sales of 26
million euros ($34 million) in the first nine months of 2012 but
posted a loss of 15 million euros.
It expects a loss before interest and tax of around 25
million euros at the unit, which has two products, for 2012.
The group said, however, it was considering keeping the
division's profitable immunosuppressive drug ATG-Fresenius S,
used in organ and stem cell transplants and which accounts for
87 percent of its sales in the biotech unit.
"ATG-Fresenius S has been well established in the hospital
market for decades, and is consistently profitable," it said in
Selling the unit's other product, cancer drug Removab
(catumaxomab), will help to improve earnings from 2013,
Fresenius other businesses include world's largest dialysis
group Fresenius Medical Care, generic infusion drug
unit Kabi, hospitals unit Helios and healthcare management
It also confirmed an outlook for group sales to rise 12-14
percent to over 19 billion euros in 2012 and for net income of
over 900 million.
($1 = 0.7641 euros)
(Reporting by Victoria Bryan)